Although Rituximab is used for treatment of B-cell lymphomas in HIV-infected patients, it is controversial and associated with high risk of infections in patients with blood CD4+ T-cell counts <100 cells/mm3 [45,46]. Here, CD4 is linked to B-cell non-Hodgkin lymphoma.